FDA Review Leader Pushes New Frameworks as CDRH Modernizes Its Approach to Innovation
At MedCon, the CDRH director outlined innovation, modernization, and new regulatory frameworks as priorities for the device center. The comments suggest the FDA is trying to keep pace with faster-moving technologies by rethinking how it evaluates products and evidence.
The CDRH director’s remarks matter because they signal intent from the top of the FDA’s device center, not just isolated policy experiments. Innovation and modernization are often used as broad themes, but in this context they point to a regulator that knows its legacy processes can lag behind software-defined and AI-enabled devices.
New frameworks are especially important in medtech because the old binary model of approval versus clearance is not always a good fit for products that learn, update, or depend on adaptive data pipelines. Regulators need mechanisms that can accommodate iteration without sacrificing patient safety. The challenge is building rules flexible enough for software while still strict enough for hardware that can directly affect diagnosis or treatment.
For manufacturers, this likely means more attention to lifecycle management, real-world performance, and ongoing evidence generation. The days when a device could be treated as static after launch are fading, particularly in digital health and AI. That shift will reward companies that invest in monitoring, usability studies, and transparent change control.
The deeper significance is cultural: the FDA appears to be trying to move from being perceived as a gatekeeper to being a framework designer. If that strategy works, it could lower uncertainty for innovators while making the evidence expectations more explicit. If it fails, the result could be a more complex regulatory landscape with little clarity gained.